Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid

被引:32
作者
Hestvik, A. L. K. [1 ]
Skorstad, G. [2 ]
Price, D. A. [3 ]
Vartdal, F. [1 ]
Holmoy, T. [1 ,2 ]
机构
[1] Rikshosp Radiumhosp, Inst Immunol, Fac Med, Oslo, Norway
[2] Ullevaal Univ Hosp, Dept Neurol, Oslo, Norway
[3] Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DU, England
关键词
multiple sclerosis; immunology; glatiramer acetate; disease modifying therapies;
D O I
10.1177/1352458508089411
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Glatiramer acetate (GA) is believed to induce GA-reactive T cells that secrete anti-inflammatory cytokines at the site of inflammation in multiple sclerosis (MS). However, GA-reactive T cells have not been established from the intrathecal compartment of MS patients, and intrathecal T cells may differ from T cells in blood. Here, we compared the phenotype of GA-reactive T cells from the cerebrospinal fluid (CSF) and blood of five MS patients treated with GA for 3-36 months, and in three of these patients also before treatment. From the CSF of these patients, all 22 T cell lines generated before and all 38 T cell lines generated during treatment were GA-reactive. GA treatment induced a more pronounced anti-inflammatory profile of GA-reactive T cell lines from CSF than from blood. While GA-reactive T cell clones from CSF were restricted by either human leukocyte antigen (HLA) -DR or HLA-DP, only HLA-DR restricted GA-reactive T cell clones were detected in blood. No cross reactivity with myelin proteins was detected in GA-reactive T cell lines or clones from CSF. These results suggest that a selected subset of GA-reactive T cells are present in the intrathecal compartment, and support an anti-inflammatory mechanism of action for GA.
引用
收藏
页码:749 / 758
页数:10
相关论文
共 50 条
  • [41] Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients
    Cross, Anne H.
    Stark, Jennifer L.
    Lauber, Joanne
    Ramsbottom, Michael J.
    Lyons, Jeri-Anne
    JOURNAL OF NEUROIMMUNOLOGY, 2006, 180 (1-2) : 63 - 70
  • [42] Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis
    Patten, S. B.
    Williams, J. V. A.
    Metz, L. M.
    MULTIPLE SCLEROSIS JOURNAL, 2008, 14 (03) : 406 - 411
  • [43] Combination therapy with interferon-beta and glatiramer acetate in multiple sclerosis
    Ytterberg, C.
    Johansson, S.
    Anderson, M.
    Olsson, D.
    Link, H.
    Holmqvist, L. W.
    von Koch, L.
    ACTA NEUROLOGICA SCANDINAVICA, 2007, 116 (02): : 96 - 99
  • [44] Effects of interferon and glatiramer acetate on cytokine patterns in multiple sclerosis patients
    Ganji, Ali
    Monfared, Mohsen Ebrahimi
    Shapoori, Shima
    Nourbakhsh, Parisa
    Ghazavi, Ali
    Ghasami, Keyvan
    Mosayebi, Ghasem
    CYTOKINE, 2020, 126
  • [45] Molecular profiling of glatiramer acetate early treatment effects in multiple sclerosis
    Anat, Achiron
    Anna, Feldman
    Michael, Gurevich
    DISEASE MARKERS, 2009, 27 (02) : 63 - 73
  • [46] Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients
    Farina, C
    Vargas, V
    Heydari, N
    Kümpfel, T
    Meinl, E
    Hohlfeld, R
    JOURNAL OF NEUROIMMUNOLOGY, 2002, 123 (1-2) : 188 - 192
  • [47] Can glatiramer acetate reduce brain atrophy development in multiple sclerosis?
    Rovaris, M
    Comi, G
    Filippi, M
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 233 (1-2) : 139 - 143
  • [48] Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis
    Kornek, B
    Bernert, G
    Balassy, C
    Geldner, J
    Prayer, D
    Feucht, M
    NEUROPEDIATRICS, 2003, 34 (03) : 120 - 126
  • [49] Neurodegeneration in multiple sclerosis and the neuroprotective effect of glatiramer acetate: a literature review
    Shmidt, T. E.
    ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2012, 112 (09) : 123 - 128
  • [50] Multiple sclerosis:: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo
    Weber, MS
    Starck, M
    Wagenpfeil, S
    Meinl, E
    Hohlfeld, R
    Farina, C
    BRAIN, 2004, 127 : 1370 - 1378